A groundbreaking phase 2 trial explores a novel, chemotherapy-free immunotherapy for relapsed indolent B-cell lymphomas, aiming to enhance patient outcomes.
ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced the launch of ResQ215B, a Phase 2 ...
Mutuum Finance (MUTM) has reported progress on its development roadmap as the project prepares for the release of its V1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results